Patents by Inventor Nicola Louise Shuker

Nicola Louise Shuker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8822455
    Abstract: The present invention relates to a fused aminodihydrothiazine derivative of formula (I): wherein R is hydrogen or C1-6alkyl, optionally substituted by one to five halogen atoms; n is 0, 1, 2 or 3; Ar is phenyl or a 5- or 6-membered heteroaromatic group containing 1, 2 or 3 N atoms, which Ar is optionally substituted by one to three substituents selected from hal, hydroxyl, —CN, C1-6alkyl, C2-3alkenyl, C2-3alkynyl, C1-6alkoxy, C3-6cycloalkoxy and pyrazine, where C1-6alkyl and C1-6alkoxy are optionally substituted by one to three halogen atoms; and pharmaceutically acceptable salts thereof; which compound has an A? production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by A? and typified by Alzheimer-type dementia.
    Type: Grant
    Filed: January 5, 2012
    Date of Patent: September 2, 2014
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Paschalis Dimopoulos, Adrian Hall, Yoichi Kita, Andrew Madin, Nicola Louise Shuker
  • Publication number: 20140011802
    Abstract: The present invention relates to a fused aminodihydrothiazine derivative of formula (I): wherein R is hydrogen or C1-6 alkyl, optionally substituted by one to five halogen atoms; n is 0, 1, 2 or 3; Ar is phenyl or a 5- or 6-membered heteroaromatic group containing 1, 2 or 3 N atoms, which Ar is optionally substituted by one to three substituents selected from hal, hydroxyl, —CN, C1-6alkyl, C2-3alkenyl, C2-3alkynyl,C-6alkoxy, C3-6cycloalkoxy and pyrazine, where C1-6alkyl and C1-6alkoxy are optionally substituted by one to three halogen atoms; and pharmaceutically acceptable salts thereof; which compound has an A? production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease 1 caused by A? and typified by Alzheimer-type dementia.
    Type: Application
    Filed: January 5, 2012
    Publication date: January 9, 2014
    Applicant: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Paschalis Dimopoulos, Adrian Hall, Yoichi Kita, Andrew Madin, Nicola Louise Shuker